Skip to search formSkip to main contentSkip to account menu

ACP-196

Known as: Bruton Tyrosine Kinase Inhibitor ACP-196 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

acalabrutinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Retraction: Abstract 408: ACP-196, An Orally Bioavailable Covalent Selective Inhibitor of Btk, Modulates the Innate Tumor Microenvironment, Exhibits Antitumor Efficacy and Enhances Gemcitabine…
The above-referenced Abstract, which was published in the August 2015 Cancer Research supplement (1), is being retracted at the… 
2016
2016
Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
A crystal form of ACP-196, a preparation method of the crystal form, a pharmaceutical composition thereof and use of the crystal… 
2015
2015
Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in…
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Pancreatic ductal adenocarcinoma exists in a… 
2014
2014
A new era in CLL treatment.
Treatment for chronic lymphocytic leukemia (CLL) is undergoing a dramatic shift: Targeted drugs are replacing the often… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)